BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KI Science Park - ECPv6.15.0.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KI Science Park
X-ORIGINAL-URL:https://kisciencepark.kisciencepark.hemsida.eu
X-WR-CALDESC:Events for KI Science Park
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230912T080000
DTEND;TZID=Europe/Stockholm:20230912T090000
DTSTAMP:20260807T015055
CREATED:20230817T152530Z
LAST-MODIFIED:20230817T152958Z
UID:10000019-1694505600-1694509200@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Reversed pitching from major Japanese pharma companies
DESCRIPTION:This free webinar will give you a great occasion to learn directly from major Japanese pharma companies about collaboration opportunities. Webinar invitation comes from Business Sweden\, Tokyo \nRegister here! \nJapan is the third largest pharmaceutical market in the world. The market size was 11.8 trillion JPY (Approx.8.9 billion SEK) in FY 2019-20. The Government of Japan has promoted the healthcare industry as an important growth engine under the country’s economic revitalization and growth strategy since 2013. Major Japanese pharmaceutical companies spend between 15% and 25% of their revenue on research and development and are moving to further expand their global operations. To further strengthen their pipelines\, they also invest in strategic alliances such as collaborative research and M&A with overseas companies\, academia. \nThe webinar will be a great opportunity for Swedish life science companies and academia to learn about research priorities and collaboration structures of major Japanese Pharmaceutical companies directly from them. \nBusiness Sweden’s Life Science in Tokyo team will also support with arrangement of one-on-one web meetings. After attending the webinar\, please send your non-confidential materials to Business Sweden Tokyo at Etsuko.yasuda@business-sweden.se indicating the companies you wish to have a follow-up meeting with\, and how your company fits their research priorities.  We will set up MS Teams meetings with those companies who agree to meet. \nSignup: No cost\, No later at 12:00 PM CET on 11th September 2023 \nProgram & the key interest areas of the Japanese Pharma companies \n8:00       Opening Remarks / Magnus Blondell\, Life Science Lead East Asia Pacific\, Business Sweden \n8:05       Japanese companies’ presentations \n\nKyouko Saita\, Ph.D.\, Business Development\, Astellas Pharma Inc.\nYuichi Tominaga\, Ph.D.\, Senior Director\, Global Business Development\, Daichi Sankyo Co.\, Ltd.\nShinobu Mitsuda\, Ph.D.\, Deputy Director\, Sohyaku Innovative Research Division\, Mitsubishi Tanabe Pharma Corporation\nHiroki Fujimoto\, Associate Director\, Business Development\, Otsuka Parmaceutical Co.\, Ltd.\nJun Hidaka\, Vice President\, Head of External Innovation\, External Innovation Department (EXID)\, Sumitomo Pharma Co.\, Ltd.\n\n8:50       Q&A \n9:00       Closing \nThe key interest areas of five Japanese Pharma companies are: \nAstellas Pharma Inc. \nAstellas is interested in cutting-edge science/technology which is leveraged in drug discovery including new biological insights\, platforms\, and modalities across multiple therapeutic areas. \n\nCell and gene therapy programs and technologies for regeneration of eye and other organs\nAAV gene therapy projects and technologies\nPrograms and technologies to modulate mitochondria related pathway\nNovel immuno-oncology programs\nTargeted protein degradation programs and technologies\nNew technologies and modalities for immune regulation\, including immunoregulatory cell therapy\nPrograms and Technologies in other emerging research areas including in vivo cell direct reprogramming\, chronobiology\, engineered phage therapy\n\nDaiichi Sankyo Co.\, Ltd. \nDaiichi Sankyo is interested in disruptive science in the preclinical phase and seeking early-stage technology platform-based opportunities for research collaboration with academia or startups. \nOncology \n\nNovel protein degradation technologies that are based on other than the ubiquitin-proteosome system\nCutting-edge technologies that enable targeting “undruggable” epigenetics-related molecules\nUnique antibodies or binders (e.g. Fab\, scFv) against tumor-associated antigens expressed on tumor\, immune\, or stromal cells that are applicable to antibody therapies and/or cell therapies\n\nCNS  \n\nPsychiatric diseases\n\n\nNovel target and psychiatric disease animal model induced by primary neuroinflammation. It is preferable there are biomarkers suitable to judge the therapeutic potential.\nResearch for endogenous ligand\, receptor\, or pathway which is expected to be involved in abnormal activity of specific brain area causing psychiatric disease. Abnormal activity of specific brain areas reported in patients and reproducibility in rodent models is recommended.\n\n\nNeurodegenerative diseases\n\n\nNovel research on glial cell function which can reveal the relevance of the progression of neurodegenerative diseases. Ideas with high originality regarding neuroinflammation\, cellular metabolism\, and senescence are of particular interest.\nResearch for finding novel therapeutic targets utilizing clinical information regarding prognosis and/or data from clinical trials.\n\nMitsubishi Tanabe Pharma Corporation \n\nDrug seeds realizing precision medicines for ALS\, MELAS\, MSA\, PSP\, FTD and ASD\nDrug seeds for targeted protein degradations or antibody drug conjugates for refractory cancers\nClinical samples\, cell models\, and animal models for above diseases\nTargeted protein degradation technologies regarding tissue specific E3 ligase\nDDS or formulation that enable oral administration of middle-molecular weight compounds\nBiomarkers that can be implemented in clinical trials for above diseases (including by wearable devices)\nMethods to identify interactions between small molecules and intrinsically disordered proteins (IDP) which cannot be isolated and purified (NMR is out of our interest)\n\nOtsuka Pharmaceutical Co.\, Ltd. \nOtsuka is focusing on Psychiatry\, Neurology\, Nephrology therapeutics and others including new MOAs\, modalities and platform technologies for our future drug discovery. \n\nEvolutionary/Innovative Science with drug candidate screening/design/selection system\nSmall molecules\, inhibit protein-protein interaction or work as protein degrader\nmRNA therapeutics with distinct nucleotide technology\nNon-viral gene therapy system\nNew and improve antibody/nucleotide delivery system (e.g. oral and high-volume SQ)\nAny novel modalities/molecules to reduce Amyloid beta oligomers or Synuclein fibrils\nTargeting DDS technology for renal and CNS diseases\n\nSumitomo Pharma Co.\, Ltd. \nSumitomo is exploring opportunities on early stage for Assets and Technologies in CNS and Oncology fields\, and Platform Technologies. \n\nPsychiatry: Drug discovery based on neural circuit pathology\nNeurology: Drug discovery based on molecular pathophysiological mechanisms\nOncology: Novel therapeutic targets or agents targeting context-dependent cancer vulnerabilities\, Novel immunotherapies\nPlatform Technologies: Drug discovery platform\, Drug delivery system\, Novel modality suitable for our focused areas
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/reversed-pitching-from-major-japanese-pharma-companies/
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2023/08/230912-bus-webevent-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230914T113000
DTEND;TZID=Europe/Stockholm:20230914T121500
DTSTAMP:20260807T015055
CREATED:20230913T203501Z
LAST-MODIFIED:20230913T204601Z
UID:10000027-1694691000-1694693700@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:AWL Running club
DESCRIPTION:Looking to boost your fitness\, meet new people\, and enjoy the outdoors? \nThe AWL Running Club is open to all tenants and meet for eight weeks with a running coach from Urban Tribes. Every session will be 45 min and we will run 3\,5-4 km. \nTIME: Thursdays at 11:30\nLOCATION: Nanna Svartz väg 4\, Campus Solna \nRegister here! \nQuestions? Send an email to Armando at:  armando.cazareskorner@akademiskahus.se
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/awl-running-club/
LOCATION:Innomedicum\, A Working Lab Cafe  |\, Nanna Svartz Väg 4\, Solna\, 171 65
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2023/09/230914-running-club.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230915
DTEND;VALUE=DATE:20230916
DTSTAMP:20260807T015055
CREATED:20230905T095934Z
LAST-MODIFIED:20230905T100020Z
UID:10000024-1694736000-1694822399@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Deadline: KI Internship program company project submission.
DESCRIPTION:Is your company looking for world-class talent in life sciences? \nThen be a part of the successful Karolinska Institutet internship program. We are looking for companies and organizations related to healthcare and life sciences who are interested in taking doctoral students and postdoctoral researchers as interns financed by KI. \nWe are now recruiting projects\, 1 to 3 months.\nOur carefully selected applicants are highly skilled\, self-driven and motivated to learn more about how to apply their transferable skills outside Academia. \nNext deadline to submit projects: September 15th\, 2023 \nInterested in knowing more?  \nInternship projects for postdocs and early career researchers \nInternship projects for PhD students \nContact us: career-service@ki.se\nKI Career Service: Ana Osório Oliveira\, Y. Vladimir Pabon-Martinez\nHead of the External Engagement Office: Richard Cowburn
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/deadline-ki-internship-program-company-project-proposal/
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2023/09/230915-deadline.jpg
END:VEVENT
END:VCALENDAR